Autopsy report · NCT03316898

A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease

“Business decision to stop the study.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Allergan

Sponsor type

Industry

Conditions

Alzheimer's Disease

Interventions

AGN-242071; Placebo; Donepezil; Memantine

Participants

0

Sites

6

Countries

United States

Trials that died the same way

• How Can a Driving Virtual Reality Tool Improve Quality of Life and Social Autonomy in Patients With Schizophrenia
  “Decision to stop the study” (91% match in meaning)
• Plaque Removal Versus Open Bypass Surgery For Critical Limb Ischemia
  “Company decision to halt study” (83% match in meaning)
• The REBALANCE Study - a Prospective, Multicenter, Randomized, Pivotal Study of the May Health System
  “Business decision by sponsor to terminate the study” (81% match in meaning)
• Safety and Efficacy of Medical Cannabis Oil in the Treatment of Patients with Chronic Pain
  “Sponsor decision to stop the study” (81% match in meaning)
• Efficacy and Safety of Iota-Carrageenan Eye Drops (NCX-4240)
  “Study stopped following management decision” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.